Nevirapine

Common brands: Epivir, Lamivudine, Retrovir, Zidovudine, Efavirenz

Top reporter: Amneal Pharmaceuticals Llc

Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]Protease Inhibitor [EPC]Cytochrome P450 3A Inhibitor [EPC]

8,934

Total Reports

2,385

Serious Reports

1,506

Death Reports

Reported Reactions

Death Report Ratio: High (16.86%)

Patient Demographics

Male

2,685

Female

2,429

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Nevirapine.

#	Reaction	Reports	% of Total
1	FOETAL EXPOSURE DURING PREGNANCY	1,112	10.6%
2	DRUG RESISTANCE	1,028	9.8%
3	VIROLOGIC FAILURE	800	7.7%
4	VIRAL MUTATION IDENTIFIED	694	6.6%
5	DEATH	496	4.7%
6	EXPOSURE DURING PREGNANCY	454	4.3%
7	HIV INFECTION	432	4.1%
8	DRUG INEFFECTIVE	406	3.9%
9	PATHOGEN RESISTANCE	382	3.7%
10	TREATMENT FAILURE	335	3.2%
11	ANAEMIA	333	3.2%
12	PYREXIA	330	3.2%
13	DRUG EXPOSURE DURING PREGNANCY	315	3.0%
14	LIPODYSTROPHY ACQUIRED	314	3.0%
15	PREMATURE BABY	252	2.4%
16	MATERNAL EXPOSURE DURING PREGNANCY	240	2.3%
17	VOMITING	219	2.1%
18	DRUG INTERACTION	213	2.0%
19	RASH	211	2.0%
20	ALANINE AMINOTRANSFERASE INCREASED	195	1.9%
21	STEVENS-JOHNSON SYNDROME	190	1.8%
22	IMMUNE RECONSTITUTION SYNDROME	175	1.7%
23	DIARRHOEA	174	1.7%
24	ABORTION SPONTANEOUS	168	1.6%
25	ASPARTATE AMINOTRANSFERASE INCREASED	168	1.6%
26	EYELID PTOSIS	168	1.6%
27	HEPATOTOXICITY	168	1.6%
28	NAUSEA	164	1.6%
29	CAESAREAN SECTION	162	1.5%
30	MITOCHONDRIAL TOXICITY	157	1.5%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.